(688137)"NOVOPROTEIN SCIENTIFIC INC."Report for Q3 2026
Filed with SSE · Stock code 688137 · · 13 pages · Chinese
Summary by 6ix AI
The report indicates that the company experienced a significant loss in net profit attributed to increased research and development expenses and asset impairment losses. The report emphasizes the accuracy and completeness of the financial information provided, with management taking legal responsibility for its contents.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Suzhou Novoprotein Scientific Co., Ltd. on 6ix
Earlier from Suzhou Novoprotein Scientific
- (688137)"NOVOPROTEIN SCIENTIFIC INC."Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
- (688137)"NOVOPROTEIN SCIENTIFIC INC."Announcement on Use of Certain Temporarily Idle Raised Funds for Cash Management
- (688137)"NOVOPROTEIN SCIENTIFIC INC."Announcement on Severe Abnormal Fluctuations in Stock Trading and Risk Warning
- (688137)"NOVOPROTEIN SCIENTIFIC INC."Announcement on Resolutions of the 21st Extraordinary Meeting of the 2nd Board of Directors
- (688137)"NOVOPROTEIN SCIENTIFIC INC."Announcement on Resignation of an Independent Director, By-election of an Independent Director and Adjustment of Members of Special Committees of the Board of Directors
Later from Suzhou Novoprotein Scientific
All Suzhou Novoprotein Scientific news releasesFollow Suzhou Novoprotein Scientific into a list and get an email when it puts out news.
Follow Suzhou Novoprotein Scientific